BENGALURU (Reuters) – Indian drugmaker Sun Pharmaceutical Industries Ltd said on Tuesday the U.S. Food and Drug Administration (FDA) had put a partial clinical hold on its application for an experimental dermatological drug due to the potential of thrombotic events.
(Reporting by Rama Venkat in Bengaluru; Editing by Rashmi Aich)
Disclaimer: This report is auto generated from the Reuters news service. ThePrint holds no responsibilty for its content.